Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Accumulated Expenses (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Other Accumulated Expenses data on record, last reported at $795000.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 33.17% year-over-year to $795000.0; the TTM value through Sep 2025 reached $795000.0, up 33.17%, while the annual FY2024 figure was $753000.0, 12.14% down from the prior year.
  • Other Accumulated Expenses reached $795000.0 in Q3 2025 per STOK's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.1 million in Q1 2025 and bottomed at $426000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 4 years is $848800.0, with a median of $750000.0 recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: decreased 12.14% in 2024, then soared 111.63% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $509000.0 in 2022, then soared by 68.37% to $857000.0 in 2023, then dropped by 12.14% to $753000.0 in 2024, then grew by 5.58% to $795000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $795000.0 in Q3 2025, $1.8 million in Q2 2025, and $2.1 million in Q1 2025.